-
-
-
-
-
-
-
Goldman Sachs Starts Biohaven Pharma (BHVN) at Buy
-
-
-
-
-
-
-
Biohaven shares cancer drug trial results at European oncology meeting
-
-
-
-
-
-
-
Piper Sandler Slashes Biohaven Pharmaceutical (BHVN) Stock PT as 'FDA Says No to Troriluzole'
-
-
-
-
-
-
-
William Blair on Biohaven (BHVN): 'Expect Weakness'
-
-
-
-
-
-
-
Biohaven Pharma (BHVN) Weakness May Be Tied to uniQure (QURE) Setback in Huntington's Disease
-
-
-
-
-
-
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $60 at BTIG
-
-
-
-
-
-
-
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Biohaven Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BHVN
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

